Subscribe
22 August 2019GenericsRory O'Neill

Novo Nordisk seeks to block Mylan generic

Danish pharmaceutical company  Novo Nordisk has sued  Mylan in a US court over a proposed generic of diabetes drug  Victoza (liraglutide).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Novo Nordisk and Sandoz settle Victoza patent suit
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Generics
Novo Nordisk and Sandoz settle Victoza patent suit
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.

More on this story

Generics
Novo Nordisk and Sandoz settle Victoza patent suit
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims